Hope may be on the horizon, however, according to a new pilot study published on June 17 in Headache: The Journal of Head and Face Pain. This discovery may lead to a novel treatment approach that ...

Migraines are one of the world's most common neurological conditions, impacting nearly 15% of people globally. Despite this widespread impact, many sufferers find current preventive treatments ...

Several anti-obesity drugs, including Ozempic, Wegovy and Mounjaro, have created buzz in the Indian markets. But are they really approved for use in India? What are their side-effects? And how much do ...

Ozempic-like drugs used to treat type 2 diabetes and obesity may also treat migraine, even when the medications don't trigger weight loss, early research suggests. A preliminary report, published ...

New research finds that men taking a GLP-1 for their obesity or type 2 diabetes often experience a rise in testosterone levels.

Researchers say GLP-1 medicines might be able to help with migraines.

Around five million Australians suffer from migraines, with women three times more likely to be affected than men ...

Medications such as Ozempic and Saxenda have grown in popularity due to their ability to treat type 2 diabetes and assist in ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life improvements occurring despite minimal weight changes.

A current weight-loss and diabetes drug has become a surprise candidate for migraine treatment, with a new pilot study showing the GLP-1 receptor agonist provided significant relief to sufferers ...

New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...